Posts by: Alice Melão

News

A combination of Adcetris (brentuximab vedotin) and dacarbazine chemotherapy may be a suitable option for frail, elderly patients with classical Hodgkin’s lymphoma who are ineligible for standard treatment, according to data ... Read more

May 21, 2018

Arranon Add-on Improves Long-term Outcomes in Young Patients with T-cell Cancers, Trial Shows

News

A combination of Arranon (nelarabine) and standard chemotherapy led to the highest survival rates seen to date in children and young adults with T-cell acute lymphoblastic leukemia (T-ALL), a Phase ... Read more

May 8, 2018

Forty Seven’s 5F9 Immunotherapy on FDA Fast Track for DLBCL, Follicular Lymphoma

News

The U.S. Food and Drug Administration has granted fast track status to Forty Seven’s lead candidate Hu5F9-G4 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. ... Read more

May 7, 2018

Arthritis Medication May Prevent GvHD, Side Effect of Stem Cell Transplants, Mouse Study Suggests

News

Baricitinib, a medicine approved in Europe for the treatment for rheumatoid arthritis, both prevented and reverted a life-threatening complication of stem cell transplants called graft-versus-host disease, a study in mice suggests. Notably, ... Read more

April 26, 2018April 26, 2018

Nearly Half of NHL Patients in Phase 1 Trial Respond to ALT-803, Rituxan Combo, Results Show

News

A combination of Rituxan (rituximab) and the experimental agent ALT-803 leads to a response rate of 48% in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma, according to preliminary data from a Phase ... Read more

April 11, 2018

Tenalisib Receives FDA Orphan Drug Status for Treatment of Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration has granted orphan drug status to investigational therapy tenalisib (RP6530) for the treatment of cutaneous T-cell lymphoma, Rhizen Pharmaceuticals announced. In December, the therapy also received orphan ... Read more

April 9, 2018

First Patient Dosed in Phase 3 Trial of Denovo’s DB102 Plus Chemo for High-risk DLBCL

News

A pivotal Phase 3 trial evaluating Denovo Biopharma‘s investigational therapy DB102 (enzastaurin) as an add-on to standard chemotherapy for high-risk diffuse large B-cell lymphoma (DLBCL) has started dosing patients. The ENGINE ... Read more

April 6, 2018

Bioniz Recruiting Patients for Phase 1/2 Trial of Its Leukemia and Lymphoma Therapy

News

Bioniz Therapeutics is recruiting certain types of leukemia and lymphoma patients for a Phase 1/2 clinical trial of its cancer therapy BNZ-1. The company is seeking people with large granular lymphocyte ... Read more

April 3, 2018

Phase 2 Study of DPX-Survivac Combo Doses First Lymphoma Patient

News

A Phase 2 trial testing Immunovaccine‘s combination of DPX-Survivac with chemotherapy and an immune checkpoint inhibitor in diffuse large B-cell lymphoma (DLBCL) has dosed its first participant. The trial is supported by Merck ... Read more

March 20, 2018March 20, 2018

Rich’s RP-323 Shows Activity Against Hodgkin’s Lymphoma in Phase 1 Trial

News

Experimental therapy RP-323 has shown anticancer activity against Hodgkin’s lymphoma in a Phase 1 trial. Its developer, Rich Pharmaceuticals, is now planning to evaluate the therapy in human clinical trials for the disease. ... Read more